Hematology News

Researchers in China determined that higher maternal periconception red blood cell folate concentration was associated with reduced risk for congenital heart disease in offspring.

Rates for CV admissions among patients with cancer has increased, according to a study published in the European Heart Journal Quality of Care & Clinical Outcomes.Primary CV admissions are highest among patients with hematological cancer with the most common cause of admission being heart failure, according to the study.

The FDA approved betibeglogene autotemcel for treatment of patients with beta-thalassemia who require routine red blood cell transfusions.

Compared with patients hospitalized with influenza, patients hospitalized with COVID-19, both before and during vaccine availability, had elevated risk for venous thromboembolism, researchers reported in JAMA.

Children with sickle cell disease living in sub-Saharan Africa do not have access to an “essential” treatment, experts wrote this week in The New England Journal of Medicine.

Prophylactic concizumab conferred an 86% reduction in treated spontaneous and traumatic bleeds among patients with hemophilia A or B with inhibitors, data from a randomized phase 3 trial showed.

A once-weekly dose of prophylactic efanesoctocog alfa conferred a significant reduction in annualized bleed rate compared with the use of prophylactic factor VIII agents, results of the pivotal phase 3 XTEND-1 study showed.

Privately insured individuals with sickle cell disease spend about $1.7 million on disease-related medical expenses during their lifetime, according to study results published in Blood Advances.

Once-monthly prophylactic fitusiran resulted in significantly fewer bleeding episodes compared with episodic-based on-demand treatment among males with hemophilia A or B with or without inhibitors, according to results of a phase 3 study.

A single infusion of verbrinacogene setparvovec resulted in normal factor IX levels among all 10 men who received the investigational gene therapy for moderate to severe hemophilia B, study results showed.